SCHEDULE: Xtant Medical Adds Nantahala Analyst to Board

Xtant Medical Holdings, Inc. announced the appointment of Abhinav Jain, an analyst from significant shareholder Nantahala Capital Management, to its Board of Directors.

Summary

• This is an Amendment No. 1 to a Schedule 13D filing by Nantahala Capital Partners Limited Partnership, Nantahala Capital Management, LLC, and its principals Wilmot B. Harkey and Daniel Mack, regarding their beneficial ownership in Xtant Medical Holdings, Inc.
• The primary purpose of this amendment is to report the election of Abhinav (Abi) Jain, an Analyst at Nantahala Capital Management (NCM), to Xtant Medical's Board of Directors on August 1, 2025.
• Mr. Jain will serve as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board.
• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack beneficially own 68,394,000 shares, representing 49.1% of Xtant Medical's Common Stock.
• Nantahala Capital Partners Limited Partnership beneficially owns 16,380,396 shares, representing 11.8% of Xtant Medical's Common Stock.
• The beneficial ownership percentages are based on 139,323,172 shares of Common Stock outstanding as of May 20, 2025.
• No other transactions in Xtant Medical Common Stock were effected by the Reporting Persons in the prior sixty days.

Sentiment

Score: 7

Explanation: The filing indicates increased shareholder engagement and oversight through a board appointment, which is generally positive for corporate governance and alignment of interests. It doesn't contain negative news or significant risks.

Positives

• Appointment of a representative from a significant shareholder (Nantahala Capital Management) to the Board of Directors, potentially enhancing shareholder alignment and oversight.
• Mr. Jain's appointment to the Compensation and Nominating and Corporate Governance Committees suggests active involvement in key governance areas.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the immediate reporting of the board appointment.

Industry Context

The appointment of a representative from a significant institutional investor to a company's board is a common practice, often signaling increased investor oversight and potential for strategic alignment. This move by Nantahala Capital Management, a substantial shareholder, suggests a desire for direct influence on Xtant Medical's corporate governance and strategic direction, which is typical in the medical device or biotech sectors where specialized knowledge and long-term investment horizons are common.

Comparison to Industry Standards

• Nantahala Capital Management's 49.1% beneficial ownership stake in Xtant Medical is a substantial position, indicating a high level of conviction and a significant influence on the company's direction, comparable to major institutional investors in other small-to-mid cap medical technology companies like Orthofix Medical Inc. or SeaSpine Holdings Corporation (prior to its merger with Orthofix), where large institutional holders often seek board representation.
• The appointment of an analyst, Abhinav Jain, to the board and key committees (Compensation and Nominating and Corporate Governance) is a standard mechanism for large shareholders to ensure their interests are represented and to contribute to strategic decision-making and executive oversight, aligning with best practices for corporate governance observed in companies with concentrated ownership.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Increased representation of a major institutional investor on the board may lead to better alignment of interests and potentially more disciplined capital allocation and strategic decisions.
• Management: The new board member, representing a significant shareholder, may bring additional scrutiny and strategic input to management decisions.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Nantahala Capital Management, has secured a board seat, which is generally a positive development for corporate governance and shareholder alignment. However, this filing primarily reports a structural change rather than new financial performance data or strategic initiatives that would warrant a 'buy' or 'sell' recommendation. The substantial existing ownership by Nantahala suggests a long-term interest, but without further operational or financial updates, a 'hold' position is prudent to observe the impact of this governance change.

Keywords

Xtant Medical Holdings, Nantahala Capital Management, Schedule 13D, Board of Directors, Corporate Governance, Shareholder Activism, Beneficial Ownership, XTNT